Julphar Diabetes announces exclusive agreement with EMD Millipore
- United Arab Emirates: Wednesday, August 08 - 2012 at 13:18
- PRESS RELEASE
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, announced an exclusive agreement to sell recombinant human insulin manufactured by the United Arab Emirates based pharmaceutical production company Julphar Diabetes.
CellPrime Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines.
It also effectively enhances cell growth rate and therapeutic protein production, while preventing morphological abnormalities of the cells.
"CellPrime Insulin will help the bio pharmaceutical industry enhance cell culture performance without sacrificing safety," said Burghard Freiberg, Senior Vice President Pharm Chemicals Solutions.
"Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials, it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective."
Joe Saldanha, GM of Julphar Diabetes said, "this agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that our state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such strong partner in the life science sector."
Julphar Diabetes is the division of Julphar that manages the manufacturing and commercialization of diabetes products.
The Julphar Diabetes facility (Julphar XI) is built in accordance with the latest EMEA regulations, utilizing the best available technologies in the market to comply with the latest international quality standards.
EMD Millipore partnered Julphar Diabetes as its source for recombinant human insulin as the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries.
The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency.
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / 4C. AME Info FZ LLC / 4C is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.